Advertisement


Louis Burt Nabors, MD, on Primary and Recurrent Gliomas: Notable Developments in Management

2016 NCCN Annual Conference (1)

Advertisement

Louis Burt Nabors, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, discusses improvements in the 2016 NCCN Guidelines for glioma, anaplastic oligodendroglioma, and glioblastoma.



Related Videos

Gynecologic Cancers

Nadeem Abu-Rustum, MD, on Cervical Cancer: Evolving Treatment Strategies

Nadeem Abu-Rustum, MD, of Memorial Sloan Kettering Cancer Center, discusses improvements in fertility-sparing surgery for young women, advances in lymph node assessment, and the evolving role of chemotherapy and radiation.

Leukemia

Jerald Radich, MD, on Chronic Myeloid Leukemia: Managing Advanced-Phase Disease

Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center, discusses ways to prevent advanced-phase chronic myeloid leukemia through adherence to prescribed treatment and routine monitoring of disease burden.

Pancreatic Cancer

Mahmoud Al-Hawary, MD, on Pancreatic Cancer: The Role of Imaging

Mahmoud Al-Hawary, MD, of the University of Michigan Comprehensive Cancer Center, discusses the role of radiology in diagnosing and staging pancreatic tumors, optimizing imaging techniques, and the value of structured reporting.

Breast Cancer

Kevin C. Oeffinger, MD, on Controversies in Breast Cancer Screening Strategies

Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.

Breast Cancer

William Gradishar, MD, on Breast Cancer Guideline Updates

William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.

Advertisement

Advertisement




Advertisement